The stock price of KoBioLabs, a KOSDAQ listed company, is strong in early trading on the 9th, following news that a U.S. patent for liver damage treatment materials has been approved.
As of 9:36 a.m. on the same day, KoBioLabs is trading at 6,000 won, up 890 won (17.42%) from the previous trading day.
The corporations specializing in microbiome drug development, KoBioLabs, noted that a U.S. patent for liver damage treatment materials used in metabolic dysfunction-associated steatotic liver disease (MASLD) had been issued the previous day.
Previously, the company confirmed the efficacy of improving liver damage in patients with insulin resistance by utilizing its own functional strains of the genus Luminococcus. Following this news, KoBioLabs surged 29.86% in its transaction and closed that day.
A representative from KoBioLabs said, "We have obtained patents in a total of six countries, including the U.S., which has the largest market size, following Korea, Japan, China, Russia, and Australia for this strain. This enables not only the acceleration of market entry through full-scale global rights acquisition but also the claim of exclusive rights in the highly scalable therapeutics market."